Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development

Compass Therapeutics Inc. (NASDAQ:CMPX) is simply a must-buy penny banal to bargain now. On November 10, Pipe Sandler expert Biren Amin reiterated that Compass Therapeutics Inc. (NASDAQ:CMPX) is simply a Buy and acceptable a $12 terms target. The affirmative stance stems from the company’s announcement that it has made important advancement successful processing its objective pipeline.

adriaticfoto/Shutterstock.com

HC Wainwright expert Joseph Pantginis besides reiterated a Buy standing connected the stock. They acceptable a $24 terms people connected November 10, buoyed by the improvement of CTX-10726, a tetravalent antibody that hinders tumor angiogenesis.

While delivering the third-quarter 2025 results, Thomas Schuetz, the Chief Executive Officer, affirmed important milestones successful the improvement of the company’s cause pipeline. For starters, the institution is signaling little mortality rates connected a randomized proceedings of tovecimig successful patients with precocious BTC. It is besides connected way to present OS and PFS information successful the archetypal 4th of adjacent year.

“These secondary endpoint information volition physique connected the statistically important superior endpoint of wide effect complaint we antecedently reported, and we expect could enactment our archetypal BLA filing successful the 2nd fractional of 2026. Recent claims-based marketplace probe shows ~25,000 patients are diagnosed with BTC annually successful the United States alone, and tovecimig could supply anticipation for the immense bulk of patients successful the 2nd enactment who person nary approved therapeutic option,” said Schuetz.

Nevertheless, the institution posted a nett nonaccomplishment of $14.3 million, oregon $0.08 per share, wider than the nett nonaccomplishment of $10.5 cardinal delivered successful the aforesaid 4th past year. A wider-than-expected nett nonaccomplishment is attributed to probe and improvement expenses expanding to $12.8 cardinal from $8.6 cardinal successful the aforesaid play the erstwhile year.

Compass Therapeutics Inc. (NASDAQ:CMPX) is simply a clinical-stage biopharmaceutical institution focused connected processing proprietary antibody-based therapies for cancer. The company’s technological absorption is connected the narration betwixt angiogenesis (the enactment of caller humor vessels), the immune system, and tumor growth.

While we admit the imaginable of CMPX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.